Overview

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease

Status:
Completed
Trial end date:
2020-08-05
Target enrollment:
Participant gender:
Summary
This is a Phase 2 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy, safety, and pharmacokinetics of KBP-5074 in patients with moderate-to-severe chronic kidney disease and uncontrolled hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
KBP Biosciences
Collaborators:
Medpace, Inc.
Worldwide Clinical Trials
Treatments:
Mineralocorticoid Receptor Antagonists
Mineralocorticoids